EP4704876A2 - Konstrukte zur deletion des menschlichen faktors vii zur behandlung von krebs - Google Patents

Konstrukte zur deletion des menschlichen faktors vii zur behandlung von krebs

Info

Publication number
EP4704876A2
EP4704876A2 EP24800412.9A EP24800412A EP4704876A2 EP 4704876 A2 EP4704876 A2 EP 4704876A2 EP 24800412 A EP24800412 A EP 24800412A EP 4704876 A2 EP4704876 A2 EP 4704876A2
Authority
EP
European Patent Office
Prior art keywords
human
cells
factor vii
gbm
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24800412.9A
Other languages
English (en)
French (fr)
Inventor
Jeongwu Lee
Hye-Min JEON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of EP4704876A2 publication Critical patent/EP4704876A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP24800412.9A 2023-05-04 2024-04-29 Konstrukte zur deletion des menschlichen faktors vii zur behandlung von krebs Pending EP4704876A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363500076P 2023-05-04 2023-05-04
PCT/US2024/026844 WO2024228958A2 (en) 2023-05-04 2024-04-29 Human factor vii deletion constructs for treating cancer

Publications (1)

Publication Number Publication Date
EP4704876A2 true EP4704876A2 (de) 2026-03-11

Family

ID=93333390

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24800412.9A Pending EP4704876A2 (de) 2023-05-04 2024-04-29 Konstrukte zur deletion des menschlichen faktors vii zur behandlung von krebs

Country Status (2)

Country Link
EP (1) EP4704876A2 (de)
WO (1) WO2024228958A2 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2683443A1 (en) * 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypeptides and uses thereof
CA2771999A1 (en) * 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
US20230123802A1 (en) * 2019-03-27 2023-04-20 Sigilon Therapeutics, Inc. Compositions, devices, and methods for factor vii therapy
EP3833381B1 (de) * 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modifizierte faktor-vii-polypeptide zur subkutanen verabreichung

Also Published As

Publication number Publication date
WO2024228958A3 (en) 2024-12-19
WO2024228958A2 (en) 2024-11-07

Similar Documents

Publication Publication Date Title
Jeon et al. Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling
Huang et al. S100A9 regulates MDSCs-mediated immune suppression via the RAGE and TLR4 signaling pathways in colorectal carcinoma
US12558369B2 (en) Compositions and methods of treating Fanconi Anemia
Fan et al. The vascular gene Apold1 is dispensable for normal development but controls angiogenesis under pathological conditions
Li et al. Tumor-infiltrating platelets promote the growth of lung adenocarcinoma
Minciacchi et al. Exploitation of the fibrinolytic system by B-cell acute lymphoblastic leukemia and its therapeutic targeting
Liao et al. AFDN deficiency promotes liver tropism of metastatic colorectal cancer
EP2831593B1 (de) S100a8/a9 als diagnostischer marker und therapeutisches target
Yang et al. Dipeptidyl peptidase IV is required for endometrial carcinoma cell proliferation and tumorigenesis via the IL‐6/STAT3 pathway
EP4704876A2 (de) Konstrukte zur deletion des menschlichen faktors vii zur behandlung von krebs
CN114410642B (zh) 一种急性t淋巴细胞白血病药物靶点及其应用
Zhao et al. Phenotypic and functional characterization of tumor‐derived endothelial cells isolated from primary human hepatocellular carcinoma
Wobus et al. Preclinical efficacy of tasquinimod in myelodysplastic neoplasms: restoring erythropoiesis and mitigating bone loss
Khan Role of Cellular Senescence in Angiotensin II Induced Oxidative Stress and Immune Checkpoint Inhibitor Efficacy in Cancer Treatment
Kabir et al. Bone marrow age dictates clonality of smooth muscle-derived cells in the atherosclerotic plaque
Bancaro ApoE-TREM2 axis induces pathogenic senescent-like myeloid cells in prostate cancer
Karim Intratumoral Fibrin As A Novel Immunomodulatory Factor In Pancreatic Ductal Adenocarcinoma
Sakil Exploring the role of p73-isoforms during tumor development
Labrèche The Role of Periostin in ErbB2-Driven Mammary Tumorigenesis and Its Gene Regulation in ErbB2+ Cancer Cells
Abruzzese et al. Prospective monitoring of chronic myeloid leukemia patients from
Abaurrea Larrañaga Oncostatin M Signalling in Cancer-Related Inflammation: Implications in Breast Cancer and Hepatocellular Carcinoma
Zhang et al. TGFβ-activated kinase-1 knockdown in hematopoietic stem-progenitor cells causes PANoptosis and myelodysplastic syndrome-like disease in mice
Aricò Interaction between tumour and microenvironment-molecular mechanisms of cell migration in canine tumours
Zhang et al. NRF1 Induces ApoEhigh Cancer-Associated Fibroblasts to Promote Stemness of Renal Cell Carcinoma
Liu et al. Placental mesenchymal stem cell-derived interleukin-6 promotes neuroblastoma progression

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251127

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR